Overview

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa. In addition, study evaluates the safety profile of phage therapy in this patient population.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
Cystic Fibrosis Foundation (CFF)